Primary systemic vasculitis

Lancet

Volumn 349, Issue 9051, 1997, Pages 553-558

  Savage, C O S ^a,b   Harper, L ^a,b   Adu, D ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ADULT; BLADDER CARCINOMA; BLOOD VESSEL WALL; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0031056295     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)80118-3     Document Type: Review

References (34)

1. Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. QJM 1948; 17: 175-205.
2. Zeek PM. Periarteritis nodosa: a critical review. Am J Clin Pathol 1952; 22: 777-90.
3. Cochrane CG, Koffler D. Immune complex disease in experimental animals and man. Adv Immunol 1973; 16: 185-264.
4. Hunder HH, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: introduction. Arthritis Rheum 1990; 33: 1065-67.
5. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
6. Scott DG, Watts RA. Classification and epidemiology of systemic vasculitis. Br J Rheumatol 1994; 33: 897-99.
7. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
8. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
9. Savage COS, Winearis CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. QJM 1985; 56: 467-83.
10. Lanham JG, Churg J. Churg-Strauss syndrome. In: Churg A, Churg J, eds. Systemic vasculitides. New York: Igaku-Shoin Medical Publishers, 1991: 101-20.
11. Churg J, Churg A. Idiopathic and secondary vasculitis: a review. Mod Pathol 1989; 2: 144-60.
12. Adu D, Howie AJ. Vasculitis in the kidney. Current Diag Pathol 1995; 2: 73-77.
13. Gross WL, Hauschild S, Mistry N. The clinical relevance of ANCA in vasculitis. Clin Exp Immunol 1993; 93 (suppl 1): 7-11.
14. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1995; 99: 49-56.
15. Gaskin G, Pusey CD. Systemic vasculitis. In: Cameron JS, Davison AM, Grunfeld J, Kerr DNS, eds. Oxford textbook of clinical nephrology. Oxford: Oxford University Press, 1992: 612-36.
16. Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titre on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994; 37: 919-24.
17. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
18. Jayne DR, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. In: Gross WL, ed. ANCA-associated vasculitides. London: Plenum Press, 1993: 469-72.
19. Richter C, Schnabel A, Csemok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995; 101: 2-7.
20. Guillevin L, Lhote F, Sauvaget F, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53: 334-37.
21. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996; 89: 15-23.
22. Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. QJM 1993; 86: 779-89.
23. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-17.
24. Stegeman CA, Tervaert JW, De Jong PE, Kalenberg CG. Trimethoprim-sulfamethoxazole (cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996; 335: 16-20.
25. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotising vasculitits. QJM 1994; 87: 671-78.
26. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the vasculitis damage index (VDI) for the standardised clinical assessment of damage in the systemic vasculitides. Arthritis Rheum (in press).
27. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36): 1 conceptual framework and item selection. Med Care 1992; 30: 473-83.
28. Esnault VLM, Testa A, Audrain M, et al. Alpha1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993; 43: 1329-32.
29. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 1994; 153: 1271-80.
30. Pall AA, Savage COS. Mechanisms of endothelial cell injury in vasculitis. Springer Semin Immunopathol 1994; 16: 23-37.
31. Brouwer E, Huitema MG, Klok PA, et al. Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model. J Exp Med 1993; 177: 905-14.
32. Carvalho D, Savage COS. Cytokines, adhesion molecules, antiendothelial cell autoantibodies and vascular disease. Cardiovascular Pathol 1996; 5: 350-67.
33. Griffith ME, Coulthart A, Pusey CD. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol 1996; 103: 253-58.
34. Rasmussen N, Jayne DR, Abramowitz D, et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995; 101(suppl 1): 29-34.